Pulmonary vascular phenotype in adults with COPD.
Clinical Registry for the Characterization of the 'Pulmonary Vascular Phenotype' in Patients With Chronic Obstructive Pulmonary Disease - a Retrospective Multi-center Data Analysis
Medical University of Graz · NCT07102823
This registry collects right-heart catheterization and clinical data from adults with COPD to better understand pulmonary hypertension in this group.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Medical University of Graz (other) |
| Locations | 3 sites (Graz and 2 other locations) |
| Trial ID | NCT07102823 on ClinicalTrials.gov |
What this trial studies
This is a multicenter observational registry enrolling adults with a clinical diagnosis of COPD who have undergone right-heart catheterization. Key hemodynamic measures recorded include mean pulmonary artery pressure (mPAP), pulmonary vascular resistance (PVR), pulmonary artery wedge pressure (PAWP), and cardiac output (CO), along with standard clinical data. Sites include the Medical University of Graz, University of Zurich, and University of Sheffield, and the project focuses on detailed phenotyping rather than testing treatments. Patients under 18 or those without RHC data are excluded, and the registry aims to correlate hemodynamics with clinical presentation and outcomes.
Who should consider this trial
Good fit: Adults (≥18 years) with a clinical diagnosis of COPD who have undergone right-heart catheterization with documented mPAP, PVR, PAWP, and CO are ideal candidates.
Not a fit: Pediatric patients, people without COPD, or those who have not had right-heart catheterization or lack complete hemodynamic data are unlikely to benefit from participation.
Why it matters
Potential benefit: If successful, the registry could help identify COPD subgroups with clinically important pulmonary vascular disease and guide earlier diagnosis and tailored management.
How similar studies have performed: Previous single-center series and registries have described pulmonary hypertension in COPD, but comprehensive multicenter RHC-based phenotyping of this 'pulmonary vascular phenotype' remains relatively limited.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * clinical diagnosis of COPD * right heart catheterization including mPAP (Mean Pulmonary Artery Pressure), PVR (Pulmonary Vascular Resistance), PAWP (Pulmonary Artery Wedge Pressure), CO (cardiac output) * age \>= 18 years Exclusion Criteria: * pediatric patients * no COPD or no RHC
Where this trial is running
Graz and 2 other locations
- Medical University of Graz — Graz, Austria (RECRUITING)
- University of Zurich — Zurich, Switzerland (RECRUITING)
- University of Sheffield — Sheffield, United Kingdom (RECRUITING)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Chronic Obstructive Pulmonary Disease, Pulmonary Hypertension, pulmonary hypertension, chronic obstructive pulmonary disease, right heart catheterization